Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Summary

To evaluate whether the cilostazol reduce neointimal hyperplasia after ZES (Zotarolimus-eluting stents) implantation, the investigators performed double-blind,randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet therapy (aspirin plus clopidogrel) for 8 months in patients with long coronary lesion treated with ZES.

Timeline

Start

2007-12

Primary completion

2009-12

Completion

2010-02

Outcome

Met primary endpoint

paper The in-stent (0.56 ± 0.55 mm vs. 0.68 ± 0.59 mm, p = 0.045) PMID 21392640 ↗

paper late loss were significantly lower in the triple versus dual group PMID 21392640 ↗

Publications

• Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ; DECLARE-LONG II Study Investigators. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011 Mar 15;57(11):1264-70. doi: 10.1016/j.jacc.2010.10.035.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cilostazol	Small molecule	100 mg	—

Indications